To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T ...

It involves inserting the segment of DNA to be copied into a cloning vector, such as a plasmid (a small, independently replicating, piece of DNA), to form a composite known as recombinant DNA.

In this valuable study, the authors demonstrate that TCF7L2 plays a role in the pathogenesis of cachexia in a mouse model of GI cancer. The results are solid, although future studies will need further ...

Gene therapy is at the cutting edge of medicine, with exciting new products being developed and used to treat a wide variety ...

ALAMEDA, Calif., April 30, 2025 /PRNewswire/ -- CellFE, a leader in non-viral gene editing technology, today announced a strategic collaboration with the Harbottle Lab at German Cancer Research ...

Biopharmas have been scaling back on AAV research for sometime now. Find out why and what's on the horizon for drug delivery ...

A startup committed to developing the world’s first universal adeno-associated viral (AAV) vector-based gene therapy for solid tumor cancers, with an initial focus on brain cancers, is borrowing ...

The gene editor -- called evoCAST -- goes a long way toward solving a problem that has confounded the development of gene therapies from the field's beginnings: How to add long stretches of DNA to ...

Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with its AAV ...